Why the study?
Does intradermal delivery of fractional doses of inactivated poliovirus vaccine induce similar serum poliovirus-neutralizing antibodies compared to intramuscular delivery of full doses in Wistar rats?
Does intradermal delivery of fractional doses of inactivated poliovirus vaccine induce similar serum poliovirus-neutralizing antibodies compared to intramuscular delivery of full doses in Wistar rats?
Intradermal delivery of fractional doses of IPV in rats achieves comparable immunogenicity to full intramuscular doses, suggesting a potential dose-sparing strategy.
Fractional intradermal IPV shows preclinical promise for dose sparing; hypothesis-generating and should not yet change practice.
Intradermal delivery of vaccines has been shown to result in dose sparing. We tested the ability of fractional doses of inactivated poliovirus vaccine (IPV) delivered intradermally to induce levels of serum poliovirus-neutralizing antibodies similar to immunization through the intramuscular route. Immunogenicity of fractional doses of IPV was studied by comparing intramuscular and intradermal immunization of Wistar rats using NanoPass MicronJet600 microneedles. Intradermal delivery of partial vaccine doses induced antibodies at titers comparable to those after immunization with full human dose delivered intramuscularly. The results suggest that intradermal delivery of IPV may lead to dose-sparing effect and reduction of the vaccination cost.
No takes yet. Share an insight, caveat, or question.
Kouiavskaia et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: